The efficacy of interleukin‐1 antagonist
drugs in combination with colchicine in patients with FMF‐AA with colchicine‐resistance after kidney transplantation: A study with histopathologic evidence

2021 ◽  
Author(s):  
Cenk Simsek ◽  
Murat Karatas ◽  
Erhan Tatar ◽  
Ali Murat Yildirim ◽  
Funda Tasli Alkan ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Interleukin 1 ◽  
Colchicine Resistance

Anakinra for constrictive pericarditis associated with incessant or recurrent pericarditis

Heart ◽  
2020 ◽  
Vol 106 (20) ◽  
pp. 1561-1565 ◽  
Author(s):  
Alessandro Andreis ◽  
Massimo Imazio ◽  
Carla Giustetto ◽  
Antonio Brucato ◽  
Yehuda Adler ◽  
...  
Keyword(s):  
Constrictive Pericarditis ◽  
Disease Duration ◽  
Interleukin 1 ◽  
Efficacy And Safety ◽  
Recurrent Pericarditis ◽  
Once Daily ◽  
Increased Risk ◽  
Colchicine Resistance ◽  
Third Line

ObjectiveFrequent flares of pericardial inflammation in recurrent or incessant pericarditis with corticosteroid dependence and colchicine resistance may represent a risk factor for constrictive pericarditis (CP). This study was aimed at the identification of CP in these patients, evaluating the efficacy and safety of anakinra, a third-line treatment based on interleukin-1 inhibition, to treat CP and prevent the need for pericardiectomy.MethodsConsecutive patients with recurrent or incessant pericarditis with corticosteroid dependence and colchicine resistance were included in a prospective cohort study from 2015 to 2018. Enrolled patients received anakinra 100 mg once daily subcutaneously. The primary end point was the occurrence of CP. A clinical and echocardiographic follow-up was performed at 1, 3, 6 months and then every 6 months.ResultsThirty-nine patients (mean age 42 years, 67% females) were assessed, with a baseline recurrence rate of 2.76 flares/patient-year and a median disease duration of 12 months (IQR 9–20). During follow-up, CP was diagnosed in 8/39 (20%) patients. After anakinra dose of 100 mg/day, 5 patients (63%) had a complete resolution of pericardial constriction within a median of 1.2 months (IQR 1–4). In other three patients (37%), CP became chronic, requiring pericardiectomy within a median of 2.8 months (IQR 2–5). CP occurred in 11 patients (28%) with incessant course, which was associated with an increased risk of CP over time (HR for CP 30.6, 95% CI 3.69 to 253.09).ConclusionsIn patients with recurrent or incessant pericarditis, anakinra may have a role in CP reversal. The risk of CP is associated with incessant rather than recurrent course.

Familial Mediterranean Fever (FMF) and Pregnancy: Literature Review

2020 ◽  
pp. 4-12
Author(s):  
П.О. Соцкий
Keyword(s):  
Familial Mediterranean Fever ◽  
Pregnancy Outcomes ◽  
Interleukin 1 ◽  
Genetically Engineered ◽  
Biological Drugs ◽  
Colchicine Resistance ◽  
Evolutionary View ◽  
Mediterranean Fever ◽  
The Impact ◽  
Colchicine Therapy

В обзоре обобщается текущая информация о влиянии семейной средиземноморской лихорадки (ССЛ) и ее лечения на исходы беременности, анализируется вопрос гипотетической тератогенности колхицина. В случае резистентности/непереносимости колхицина обсуждается возможность использования других лекарственных средств во время беременности, в том числе, генно-инженерных биологических препаратов, среди которых при ССЛ наиболее предпочтительны ингибиторы интерлейкина 1. Представлена эволюция взглядов на необходимость проведения пренатальной диагностики хромосомных аномалий плода пациенткам с ССЛ, получающим колхицин во время зачатия и беременности, а также в тех случаях, когда колхицинотерапия проводилась мужьям во время зачатия их женами. Акцент сделан на аспектах безопасности терапии, основные положения которых представлены в клинических рекомендациях по лечению ССЛ Европейской антиревматической лиги (EULAR,2016). Согласно этим рекомендациям, прием колхицина не должен быть прекращен во время зачатия, беременности или лактации; имеющаяся на сегодняшний день доказательная база не подтверждает необходимость выполнения амниоцентеза. The review summarizes current information on the impact of FMF and its treatment on pregnancy outcomes, and analyses the hypothetical teratogenicity of colchicine. In the case of colchicine resistance/intolerability, the possibility of using other drugs during pregnancy, including genetically engineered biological drugs, among which interleukin 1 inhibitors are preferred for FMF. An evolutionary view is presented on the need for amniocentesis in FMF patients receiving colchicine during conception and pregnancy, as well as in cases where colchicine therapy was performed to husbands during conception with their wives. Emphasis is placed on the safety aspects of therapy, the main provisions of which are presented in the clinical recommendations for the treatment of FMF of the European Anti-Rheumatic League (EULAR, 2016). According to these recommendations, colchicine should not be discontinued during conception, pregnancy or lactation; today’s evidence does not support amniocentesis.

1872: The Efficacy of Deoxyspergualin and Plasmapheresis for Antibody-Mediated Acute Rejection After Kidney Transplantation

2004 ◽  
Vol 171 (4S) ◽  
pp. 494-494
Author(s):  
Michio Michio Nojima ◽  
Tetsuro Yoshimoto ◽  
Atsushi Nakao ◽  
Takuo Maruyama ◽  
Hidekazu Takiuchi ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Acute Rejection

1860: Morphologic Alterations of Bladder and Intestinal Segment Following Bladder Augmentation and Kidney Transplantation

2004 ◽  
Vol 171 (4S) ◽  
pp. 491-492
Author(s):  
William C. Nahas ◽  
Paulo R. Gianini ◽  
Luiz B. Saldanha ◽  
Eduardo Mazzucchi ◽  
Joannis Antonopoulos ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Bladder Augmentation ◽  
Intestinal Segment

1949: Six Month Randomized Study Comparing Cyclosporine Microemulsion with C2 Monitoring and Tacrolimus in De Novo Kidney Transplantation

2004 ◽  
Vol 171 (4S) ◽  
pp. 515-515
Author(s):  
Felipe G. Balbontin ◽  
Bryce Kiberd ◽  
Philip Belitsky ◽  
Dharm Singh ◽  
Albert Fraser ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
De Novo ◽  
Randomized Study ◽  
C2 Monitoring ◽  
Cyclosporine Microemulsion
Sign in / Sign up

Export Citation Format

Share Document